WHAT’S INSIDE 3 Our New Alliance with The Michael J. Fox Foundation • 4 Genetically Engineered Mouse • 5 2013 Research Grants • 6 Golf Invitational • 7 Fashion Supports Research

OutlookFA L L 2014

Partnersin

Progress

CO-FOUNDERSLouis Bachmann (1916 – 2000)Bonnie Strauss

BOARD OF DIRECTORSBonnie Strauss, Founder & PresidentThomas W. Strauss, Vice President & TreasurerNancy L. Rackoff, Esq., Secretary

Felice AxelrodMitchell F. Brin, MDTed Dawson, MD, PhDJudith Ann Eisenberg Ron HershMasahiko KasugaLoren M. KatzovitzThomas G. LoebAllison LondonJames C. MarlasJohn PomerantzJeffrey SilvermanJason SpacekGregg SpielbergMark StandishChris Von Der Ahe Jonathan D. Zames

SCIENTIFIC ADVISORY BOARDTed Dawson, MD, PhD, Chair

Charles Adler, MD, PhDKailash Bhatia, MD, DM, FRCPDavid Borchelt, PhDSusan B. Bressman, MDMitchell F. Brin, MDNicole Calakos, MD, PhDMarie-Francoise Chesselet, MD, PhDMahlon DeLong, MD, DMRF Liaison ex officioWilliam Dauer, MDAnn M. Graybiel, PhDPhyllis Hanson, MD, PhDJohn A. Hardy, PhDEllen Hess, PhDChristine Klein, MDEric J. Nestler, MD, PhDHenry Paulson, MD, PhDDavid Standaert, MD, PhDD. James Surmeier, PhDThomas Wichmann, MDC. Warren Olanow, MD, FRCPC, Honorary Chair

BOARD OF SPECIAL ADVISORSDr. Max GomezChristian HoffRobert F. Kennedy, Jr.Pia LindstromHon. Janet Reno

SPOKESPERSONWillie Geist

EXECUTIVE DIRECTORPaula K. Stein

When I was first diagnosed with dystonia, my father, Lou Bachmann, gave me great

advice. He told me I had a choice. I could sit back and wait for others to find a cure,

or I could be proactive and “make a difference.” I chose the second option by starting

The Bachmann-Strauss Dystonia & Parkinson Foundation (BSDPF) and I could not be

more proud of the results.

Over the past twenty years, our Foundation has

built a legacy of excellence in dystonia and Parkin-

son’s disease research thanks to your loyal friend-

ship and generous support. With your help, we

have raised $35 million to seed the discovery of

new genes, potential drug targets and advances in

technology that are paving the way for better treat-

ments and cures. We have also provided $1.6 million

to open four Dystonia and Parkinson’s Disease

Centers of Excellence that are setting the standard

of one-stop patient-centered care for the dystonia

and Parkinson’s disease community. And none of this

could have happened without you.

But we can and absolutely must do more!

I am thrilled to announce that we are forming a

collaborative research alliance with The Michael J.

Fox Foundation (MJFF) that will lead to even greater

progress. Beginning January 1, 2015, we will be estab-

lishing The Bachmann-Strauss Prize for Excellence in

Dystonia Research in partnership with the Michael J.

Fox Foundation. Additionally, we are joining forces to

support research that explores overlaps in the under-

lying causes, development and treatment of dystonia

and Parkinson’s disease. This means that we will be

discontinuing our regular grantmaking program at

the end of the year and refocusing our energy and

resources in support of our alliance with MJFF.

MJFF is an ideal match for us because of our

decade-long working relationship with them and the

wealth of resources they provide in helping us raise

awareness and support of dystonia and Parkinson’s

research. Our partnership also leverages pre-existing

relationships we have in common with scientific

advisers, researchers and patients.

As you know, we have always had a dual mission of

funding research to find better treatments for both

dystonia and Parkinson’s. By partnering with MJFF

now and taking on this new role, we can leverage

their prestigious platform to bring more attention to

dystonia, which is an under-funded disorder and an

under-recognized symptom of Parkinson’s. In fact,

some experts estimate that 40 percent of PD patients

have dystonia.

Joining forces with MJFF will enable us to make a

bigger impact and generate greater awareness on a

much larger and luminous stage. And while we will

be closing our doors physically, the spirit of our work

will live on under the careful stewardship of MJFF.

In the coming months you will receive informa-

tion about important ways that you can continue to

support our programs through our partnership with

MJFF. In lieu of our annual golf tournament, there

will be a very special event in May 2015 to celebrate

the past and embrace an extraordinary future. I hope

you will join us.

With deepest appreciation,

Bonnie StraussFounder & President

Bonnie StraussFounder and President

OUTLOOK SUMMER 2014

The Bachmann-Strauss Dystonia & Parkinson Foundation, Inc.

Foundation Update

2

Partners in Progress:

Bachmann-Strauss Foundation Forms Groundbreaking Research Alliance with The Michael J. Fox FoundationMoving forward, Bachmann-Strauss embraces an extraordinary future.

For 20 years The Bachmann-Strauss Dystonia and Parkinson Foundation (BSDPF) has been a leader in raising awareness about dystonia and support-

ing research to find treatments and even a cure for this under-funded and under-recognized movement disorder. Now BSDPF is advancing this important cause through a unique col-laborative research alliance with The Michael J. Fox Foundation (MJFF). This partnership will facilitate greater visibility and deeper investment in advancing dystonia and Parkinson’s disease re-search. Through the alliance, BSDPF is establish-ing The Bachmann-Strauss Prize for Excellence in Dystonia Research—a major award to expand public awareness, acknowledge key scientific discoveries and incentivize the work of dedicated researchers in dystonia.

In its search to find a partner, BSDPF sought an organization that could bring greater prominence to dystonia. The relatively limited population of people affected by the disease makes it challenging to generate awareness and attract research funding. “We are thrilled to be aligning with MJFF now and taking on a new role,” says BSDPF founder and president Bonnie Strauss. “This partnership offers opportunities to generate greater exposure to dystonia through MJFF’s global network.” According to CEO Todd Sherer, PhD, MJFF has an outstand-ing track record of leveraging significant resources in areas that overlap between Parkinson’s and dystonia research. The work they have supported in basal ganglia circuitry and deep brain stimulation surgery has been of signifi-cant benefit to dystonia patients.

“Bachmann-Strauss has been a valued partner to us for many years,” says Sherer. “We share a commitment to advancing research that will lead to transformative medical treat-ments patients so urgently need. In creating this

3

A new partnership offers opportunities to generate greater

exposure to dystonia via a global network.

Continued on page 4

alliance, MJFF’s drive to accelerate Parkinson’s drug development continues to move forward. Partnering with BSDPF allows us to deepen our work together in support of high-impact scien-tific findings that will benefit both dystonia and Parkinson’s patients.”

Most people are not aware of the close connec-tion between dystonia and Parkinson’s disease. Some experts believe that 40% of people with Parkinson’s also have dystonia. Because few physicians are familiar with the symptoms of dys-tonia, which affects approximately half a million people in North America, many patients suffer

for years before getting a proper diagnosis. Help-ing them has been a key element of BSDPF’s mission.

Under the leadership of Bonnie Strauss, BSDPF has raised over $35 million and funded 235 research grants for dystonia and Parkinson’s disease. Projects supported by the Foundation have led to great advances over the past two decades. The recent discovery of three new dys-tonia-implicated genes has increased understand-ing of the causes of the disease, leading to novel therapeutic targets. The Foundation has also provided a brighter future for patients through

OUTLOOK SUMMER 2014

4

the establishment of four Centers of Excel-lence, bringing together “one-stop” clinical care and support services for people with dystonia and Parkinson’s disease. Advances in deep brain stimulation surgery, including improved precision and safety, have ex-panded the use of this technique to enhance quality of life for people with dystonia.

Beginning January 1, BSDPF will discon-tinue its regular grantmaking program and refocus its energy and resources in support of The Bachmann-Strauss Prize for Excel-lence in Dystonia Research. The Prize will honor a scientist who has made profound contributions to dystonia research, with preference given to individuals who have made major discoveries with clear pa-

tient relevance. The award will include an unrestricted grant of $100,000 to sup-port further research. A Prize committee comprised of experts in neuroscience will convene annually to nominate potential award recipients and select the winner. The committee, to be chaired by Ted Daw-son, MD, PhD, the Leonard and Madlyn Abramson Professor of Neurodegenerative Diseases at The Johns Hopkins University School of Medicine, will also include one individual personally affected by dystonia. Bonnie Strauss will serve in this role. The first Prize will be presented in New York City in May 2015.

 “We are so grateful for the outstanding support we’ve received through the years,” says Strauss. “The spirit of our work will live on through The Bachmann-Strauss Prize for Excellence in Dystonia Research and under the thoughtful leadership and stewardship of MJFF.”

Genetically Engineered Mouse Mimics Human Form of DystoniaWHY DO some people develop dystonia? What can be done to prevent or treat it? For years, these questions have plagued physicians who treat patients with this debilitating movement disorder. Now, new research from the University of Michigan (U–M) may finally provide some answers.

A team of researchers led by neurologist and Bachmann-Strauss Advisory Board member William Dauer, MD, has developed a new strain of mice that closely mimics the symptoms of dystonia, which include uncontrollable twisting, stiffening and spasms of muscles in the neck and limbs. A paper published in the Journal of Clini-cal Investigation details discoveries about dystonia made from studying the mice.

“We’ve created a model for understanding why certain parts of the brain are affected by genetic mutations,” says the scientist. “Down the road, we hope this will help us develop new thera-pies for patients.” There are currently no drugs designed specifically for dystonia.

“Many researchers, including our team, have had success over the years in developing animal models to study dystonia, but until now none had the distorted movements so characteristic of the disorder,” explains Dauer, who is direc-

tor of the Movement Disorders Group and the Elinor Levine Professor of Neurology at U-M and a Bachmann-Strauss Impact Grant recipient. “While these models have been helpful, without the dystonic movements their value is limited.” The U-M model (photo, below) is the first to exhibit the dystonic movements and stiff, twisted limbs that mimic the symptoms of dystonia in humans.

This new model was 17 years in the making. The research team faced setbacks and failure trying to figure out how and why a certain gene defect leads to an inherited form of dystonia that doesn’t start until the preteen or teen years. The gene defect, called DYT1, causes brain cells to make a less active form of a protein called torsinA.

The team used genetic technology to impair torsinA function during early brain development. This caused the new mice to develop dystonia during the mouse equivalent of the preteen years, the time that many humans develop symptoms. The team found that the lack of torsinA in the brains of the new mice led to the death of neurons to certain areas of the brain that control movement.

“The Foundation has done much to raise awareness about dystonia, which has been of

invaluable help in expand-ing and enhancing the dystonia network,” says Dauer. “They’ve also made outstanding contributions to clinical care. Through the establishment of their Dystonia and Parkinson’s Disease Centers of Excel-lence, they’re connecting patients with the experts who can help them.”

Above: William Dauer, MD (center), with his research team. Right: Just like people with dystonia, this mouse’s limbs twist and extend uncontrollably—allowing researchers to study the disorder’s causes and potential treatment.

Partners in ProgressContinued from page 3

This collaboration will strengthen work supporting

scientific findings to benefit both dystonia and

Parkinson’s patients.

Foundation’s 2013 Research Grants

Support InnovationThe Bachmann-Strauss Dystonia & Parkinson Foundation

supports innovative scientific research and passionate, dedicated

scientists. Our primary research grants provide seed money for new approaches and

have helped to bring greater insight into the causes and cures for dystonia and Parkin-

son’s disease. The Foundation funded nine outstanding investigators in 2013.

DYSTONIA GRANTSTatiana (Tania) Fuchs, PhDIcahn School of Medicine at Mount Sinai • New York, New York

Gene Discovery in Familial Cervical Dystonia*

Cervical dystonia (CD) is one of the most common forms of primary focal dystonia. The research funded by this grant is focused on finding a genetic cause for CD. The lab is using an innovative, powerful technique to screen all genes in ten unrelated familial CD patients to identify potential candidate genes. These genes will be screened in other CD patients to identify CD causative gene(s). This research will uncover a new causative gene for CD and help us better understand the disease mechanism. Additionally, the study may provide a basis for the development of new therapies.

Karel Liem, MD, PhDYale School of Medicine • New Haven, Connecticut

Characterization of a Novel Mouse Mutant of the DYT4-Associated Gene Tubb4a*

Tubb4a is expressed by specific cell populations within the brain and spinal cord and has been identified as a gene associated with the hereditary dystonia DYT4. The neural processes disrupted by Tubb4a mutations that lead to dysto-nia are unknown. Our lab has generated a mouse mutant of Tubb4a that develops a dystonic phenotype with the hope that it will help us better understand the neural circuits and cellular pathways that are disrupted in dystonia. We are using mouse genetics to better characterize and identify the disrupted neural cells. This will lead to better understand-ing of DYT4 and other dystonias and potentially support development of new therapies.

Roy Vincent Sillitoe, PhDBaylor College of Medicine • Houston, Texas

Determining the Trigger for Cerebellar Dystonia*

Defects in brain communication are always involved in dystonia. While studies have shown that communication problems in the cerebellum can cause the disease, the mechanism of this defective communication is unclear. Using mouse models, the lab is examining the mechanisms that trigger this cerebellar miscommunication. The lab’s strategy is to genetically manipulate the function of specific connections called synapses. They hypothesize that the cerebellum may have one type of synapse that is extremely susceptible to dystonia pathogenesis. Therefore, altering its function may be a major trigger for the disease. They have found that altering this synapse causes severe dystonia in mice, with a striking similarity to what is observed in humans. This model offers an ideal strategy with which to validate potential treatments.

Veronique VanderHorst, MD, PhD Beth Israel Deaconess Medical Center • Boston, Massachusetts

Cholinergic Spinal Interneurons Mediating Regional Dystonic Phenotypes*

The neural circuitries that mediate the twisting movements of dystonia are not fully understood. Insight into these circuitries is relevant as they may be involved in various types of dystonia or could form potential new targets for intervention. The lab is using a novel technology, called Designer Receptors Exclusively Activated by Designer Drugs (DREADD), to study the role of cholinergic circuitries in the spinal cord in dystonia. Small clusters of spinal cholinergic neurons can be reversibly activated by a designer drug that does not affect other neurons. Following activation, dystonia-like phenotypes are elicited. The lab is examining what changes occur following activation. A role of these spinal cholinergic circuits in dystonia will help to develop improved interventional strategies.

PARKINSON’S DISEASE GRANTSAiqun Li, PhD The New York Stem Cell Foundation • New York, New York

Development of an Automated Process to Obtain Reproducible Panels of Purified Dopamine-Producing Cells for Modeling Parkinson’s Disease

Induced pluripotent stem (iPS) cells provide a novel platform to evaluate how genetic and environmental risks contribute to Parkinson’s disease (PD). The lab analyzed whether iPS cell-derived midbrain dopamine-producing (mDA) neurons generated from controls differed from PD patients, including a pair of identical twins (one has PD, the other does not) carrying the mutated glucocerebrosidase (GBA N370S). Purified mDA neurons derived from the PD twin were found to have elevated alpha-synuclein, decreased GBA activity, low dopamine level and up-regulated monoamine oxidase. The team is determining whether the phenotype is specific to these samples, to those affected by PD who have a GBA mutation, or the broader PD community. They propose the improved neuronal purification from the differentiated cul-ture, which reduces the intra- and inter-cell line variations in the human disease-in-a-dish model. This is key to studying multiple risks related to PD pathology.

Brian Mathur, PhD University of Maryland School of Medicine Baltimore, Maryland

Serotonergic Control of Corticostriatal Synapses in L-DOPA-Induced Dyskinesia

Therapeutic L-DOPA, treatment for the symptoms of Parkin-son’s disease (PD), serves to replenish dopamine levels in

the striatum, an area of the brain that is critical to normal motor function. L-DOPA is initially effective in alleviating PD motor symptoms. However, after five to ten years, dyskine-sias develop, hampering patient quality of life. Dyskinesia development is linked to dysfunction in two neurotransmit-ter systems within the striatum. The lab is studying how interactions between these two systems contribute to the development of L-DOPA-induced dyskinesia in a mouse model of PD. This work may provide novel strategies for therapeutic intervention in L-DOPA-induced dyskinesia.

Narayanan Nandakumar, MD, PhDUniversity of Iowa • Iowa City, Iowa

Serotonin Neuron and Dyskinesias in Parkinson’s Disease

One devastating side effect of treatment for Parkinson’s disease (PD) is dyskinesias, or involuntary movements that are difficult to control. Evidence from rodent work suggests that serotonin can influence dyskinesias, but is unknown how this works. Here, we record from neural activity of populations of striatal neurons while manipulating serotonin neurons. We hope that this will identify how serotonin neurons influence dyskinesias, and could lead to new, highly targeted treatments for PD and other movement disorders.

OVERLAP GRANTS (DYSTONIA AND PARKINSON’S DISEASE)

Louis Ptacek, MD University of California, San Francisco • San Francisco, California

Generation of PRRT2 Knock-Out Model of Paroxysmal Kinesigenic Dyskinesia

Paroxysmal kinesigenic dyskinesia (PKD) is a movement disorder characterized by child onset episodes of choreo-athetosis and dystonia, triggered by sudden movements. Benign infantile convulsions are a part of the phenotype but typically resolve and are sometimes forgotten once a patient is experiencing hundreds of movement disorder attacks each day. The team has cloned the genes causing PKD and a related disorder and is generating mouse models for further study, which may lead to better diagnosis and treatment of paroxysmal dyskinesias. In addition, better understanding of dopamine signaling and dysregulation in PKD may provide insights into new treatments for other movement disorders like Parkinson’s disease.

John Hardy, PhD UCL Institute of Neurology • London, UK

Development of a Neuronal Model of PANK2 Associ-ated Neurodegeneration with Brain Iron Accumulation (NBIA)

Neurodegeneration with brain iron (NBIA) is the name of a family of related diseases which resemble Parkinson’s disease, but are more severe. We and others have found six different genetic forms of the disease. We are studying these rare recessive diseases, taking small skin cell samples from consenting patients and reprogramming these cells into neurons using the new technology for which Shinya Yamanaka was recently awarded the Nobel Prize. We will then study these neurons to understand exactly how the causative mutations disrupt the cell’s metabolism.

*A Jake’s Ride for Dystonia Research Grant

5

OUTLOOK SUMMER 2014

6

Golf Invitational Raises More Than $1.1 MillionSTEPPING FORWARD TOWARDS A CURE was the theme of The Bachmann-Strauss Foundation’s 22nd Annual Golf Invitational, held on June 16. Participants did indeed step forward, raising more than $1.1 million to help fund dystonia and Parkinson’s disease research.

The event included a buffet lunch, Pro-Am golf tournament, cocktails, a live auction and dinner. Willie Geist, co-host of NBC’s Today’s Take and MSNBC’s Morning Joe, served as emcee.

Auctioneer Jamie Niven, chairman of Sotheby’s, once again hosted the live auction, which raised $160,400, making it the Foundation’s most successful auction in six years.

Teenager Ben Collier, an avid tennis and piano player who was recently diagnosed with dystonia, spoke about the challenges of living with this disorder. Concert pianist Gohei Nishikawa, who also suffers from dystonia, performed during the evening program. Laurie Ozelius, PhD, of Mount Sinai’s Carl Icahn School of Medicine, gave an update on advancements in research and the challenges ahead in finding better treatments and cures. Celeste Fisher, introduced by Young Leadership Council chair Allison London, received the Scott M. Johnson Memorial Award. The Foundation offers heartfelt thanks to all the supporters who made the event such a great success.

Left: Edith Tuckerman. Top, left to right: Ben Collier, Allison London, Celeste Fisher, Gohei Nishikawa and Willie Geist. Center, left: Jamie Niven; right: Ron Hersh bidding at the live auction. Bottom, left to right: Patrick Robertson, Paul Uhlman, Ben Collier, Charlie Collier and Lenny Kuperman with their caddie (front).

Celebrating Dystonia Awareness MonthMANY EXCITING EVENTS were held in September, Dystonia Awareness Month, to educate the public about this debilitating movement disorder. Top: The Bachmann-Strauss Foundation had the opportunity to design a dystonia awareness window display at 10 Rockefeller Plaza. Bottom: A group of dys-tonia advocates came together in that same Rockefeller Plaza to make an “Orange Splash” at NBC’s TODAY show. Orange is the color of dystonia awareness.

Car Lovers Support ResearchIN 2009, Josh and Jeremy Mosier of Austin, TX, were preparing for their bar mitzvahs and came up with a great idea for a mitzvah project. They would hold a car show in honor of their cousin, Jacob Spielberg, who has dystonia and faces many challenges. “Cars for Parkinson’s and Dystonia” has grown into an annual event organized by the two Mosier families. It attracts car aficionados who bring classic or collect-ible cars for display. This year’s show attracted some 450 attendees and several sponsors and raised more than $35,000.

Another fund-raiser, “Cars & Coffee,” is held in Louisville, KY, twice a month. Car lov-ers bring their rides to Captain’s Quarters, a popular local restaurant. This event, started by Gregg Spielberg, Jacob’s dad and a Bachmann-Strauss board member, raises approximately $1,000 a month to support dystonia and Parkinson’s disease programs.

7

Jake Silverman: A Life Transformed by Research WHEN 10-year-old Jake Silverman was diag-nosed with dystonia in 2008, his symptoms were so severe he had to use a wheelchair. “I had no idea what my future held,” says Jake.

His family never gave up trying to find a way for their son to prevail over his disease. And he’s done better than they ever imagined. After graduating from high school this summer, Jake, now 17, traveled across Europe with a friend. And last month, Jake began his freshman year at American University. “It’s a dream come true for all of us,” says his mother Nancy Silverman.

Jake underwent deep brain stimulation surgery (DBS) the same year he was diagnosed. While he’s made amazing progress, his dystonia is not cured. Despite numerous setbacks, including DBS battery malfunctions, he’s learned how to manage his illness.

Jake’s family and friends came to the Founda-tion in 2008 to launch the annual Jake’s Ride

for Dystonia Research. Since then, $2 million has been raised to support research. This year’s ride, held on September 29, raised more than $306,000.

“Our goal is to educate more people about dystonia,” stresses Nancy. “Finding the right doctor is so important. That’s what made the difference for Jake.”

For more information, visit jakesride.org.

Left: The Silverman family, the Gardner family and Willie Geist at the 2014 Jake’s Ride. Above: Jake Silverman with friends before having deep brain stimulation surgery at age 10.

Running theMarathon

WithTeam Bachmann-Strauss

EACH YEAR Bachmann-Strauss fields a teamto run in the TCS New York City Marathon inhonor of those livingwith dystonia and Parkin-son’s disease. Meeta few members of thisyear’s team and learnwhy they’re committed.

Runner Elena Viglianco-Espinosa, 35, was inspired by her 77-year-old mother’s bravery in dealing with dystonia. “She struggled for years until she was diagnosed in 2013,” she says. “I want to show the same strength and determination she demonstrates.”

Brothers Daniel and Michael Feder will run to support their father, who has Parkinson’s disease. “It’s our birthday gift to our dad,” says 27-year-old Michael, a business consultant. Adds Daniel, 23, an analyst with a Manhattan law firm: “Knowing I can help him and others with Par-kinson’s inspires me.”

Elena Viglianco-Espinosa

Daniel and Michael Feder

Fashion is Our FriendTHE FASHION INDUSTRY has been a great friend to the Foundation. We’re grateful to have been the beneficiary of several exciting events in the world of fashion—all organized with a goal of raising funds to find better treatments and cures for dystonia and Parkinson’s disease.

We’d like to thank fashion designer Rebecca Taylor for her support of our mission. Three shop-ping fundraisers were held at Rebecca Taylor boutiques in New York and Los Angeles during the

past year. The most recent one held April 10 included a special Vale Jewelry trunk show to benefit the Founda-tion. The Rebecca Taylor events have raised $36,000 for the Foundation. “Our relationship with Bachmann-Strauss is special,” says Rebecca Taylor CEO Beth Bugdaycay. “We’ve never worked with a more engaged group. We’re proud to be part of this partnership.”

This summer, Rebecca Taylor also designed a stylish silk and lace inset blouse in honor of the Founda-tion. Proceeds from the sale of this blouse during the month of June were donated to support research.

The weather was more than perfect for the fashion block party held on Greenwich Village’s chic Bleecker Street over the weekend of June 21. Bachmann-Strauss’ Young Leadership Council helped organize the event. A total of $15,000—ten percent of sales from participating stores—was donated to the Foundation to support research.The Foundation thanks the participating merchants and boutiques, including Rebecca Taylor, Alexis Bittar, Black Fleece by Brooks Brothers, Cynthia Rowley, Diptyque, GANT Rugger, James Perse Men, James Perse Women, Jimmy Choo, Mulberry, Robert Graham, Robert Mark Eyewear, Sucre, Van Leeuwen Artisan Ice Cream, Westville and WiNK.

Top: Alana Zinn Beyda, Jeremy Beyda and Jacob Beyda enjoying Van Leeuwen ice cream at the fashion block party. Bottom: June Hersh and Ron Hersh shopping for the cause.

Fred French Building551 Fifth Avenue, Suite 520New York, NY 10176

Phone 212-682-9900Fax 212-682-6156

www.dystonia-parkinson.org

SAVETHE

DATE

2014 Sunday, November 3TCS New York City Marathon

Come cheer on members of TEAM Bachmann-Strauss who are running to benefit dystonia and Parkinson’s disease research

www.teambachmannstrauss.kintera.org

Wednesday, November 19Theater Benefit: The Last Ship

Neil Simon Theater

New York, NY

Wednesday, May 13The Bachmann-Strauss Foundation Celebratory Dinner

The Pierre

New York, NY

Your support is greatly appreciated. To learn more or make a donation visit www.dystonia-parkinson.org or call 212-682-9900.

The Bachmann-Strauss Dystonia & Parkinson Foundation, Inc. was established in 1995 to find better treatments and cures for the movement disorders dystonia and Parkinson’s disease, and to provide medical and patient information. An independent, nonprofit, 501(c)3 organization, its funding is made possible through the generosity of individual and corporate contributors.